Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
Sanofi and Alnylam have agreed to conclude the research and option phase of the companies’ 2014 RNAi therapeutics alliance in rare genetic diseases. The material collaboration terms for…
Read More...
Read More...
